<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Par13">Additionally, patients who received the Pfizer COVID-19 vaccine experienced significantly better survival and lower rates of intracranial hemorrhage, venous thromboembolism, and acute myocardial infarction compared to unvaccinated patients; however, this relationship was not observed in the Moderna vaccine cohort. This suggests that Pfizer vaccination may more effectively reduce the risk of AIS sequelae after COVID-19 infection compared to Moderna vaccination. By contrast, there is evidence that the Moderna vaccine is more effective in preventing severe COVID-19<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, so more research is needed into this comparison.</p>